Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial

Dinesh Khanna^*, Christopher P. Denton, Angelika Jahreis, Jacob M. van Laar, Tracy M. Frech, Marina E. Anderson, Murray Baron, Lorinda Chung, Gerhard Fierlbeck, Santhanam Lakshminarayanan, Yannick Allanore, Janet E. Pope, Gabriela Riemekasten, Virginia Steen, Ulf Müller-Ladner, Robert Lafyatis, Giuseppina Stifano, Helen Spotswood, Haiyin Chen-Harris, Sebastian DziadekAlyssa Morimoto, Thierry Sornasse, Jeffrey Siegel, Daniel E. Furst

^*Corresponding author for this work

Clinic of Rheumatology

University of Michigan
University of London
Genentech Incorporated
Utrecht University
University of Utah
University of Liverpool
McGill University
Department of Veterans Affairs Palo Alto Healthcare System
University of Tubingen
University of Connecticut Health Center
Université Paris Descartes
Georgetown University
University of Giessen
Boston University School of Medicine
Roche Products Ltd
Pharma Research and Early Development (pRED)
California State University Los Angeles

Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial

Fingerprint

Medicine and Dentistry

Immunology and Microbiology

Biochemistry, Genetics and Molecular Biology